PMID- 33327893
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 19
DP  - 2020 Jan-Dec
TI  - Upregulation of Serum lncRNA DLEU1 Predicts Progression of Premalignant 
      Endometrial Lesion and Unfavorable Clinical Outcome of Endometrial Cancer.
PG  - 1533033820965589
LID - 10.1177/1533033820965589 [doi]
LID - 1533033820965589
AB  - OBJECTIVE: Long non-coding RNAs (lncRNAs) play a critical role in tumorigenesis. 
      Upregulation of lncRNA deleted in lymphocytic leukemia 1 (DLEU1) has been 
      reported in endometrial cancer (EC) tissues. This prospective study aimed to 
      determine the potential clinical significance of serum lncRNA DLEU1 in EC. 
      METHODS: The serum lncRNA DLEU1 level was detected in EC patients, patients with 
      endometrial hyperplasia and healthy controls by reverse 
      transcription-quantitative polymerase chain reaction (RT-qPCR). Then its clinical 
      value in EC was further evaluated. RESULTS: Our results demonstrated that serum 
      lncRNA DLEU1 levels were significantly increased in patients with EC, and serum 
      lncRNA DLEU1 showed good performance for discriminating EC patients from patients 
      with endometrial hyperplasia and healthy controls. In addition, EC patients with 
      advanced clinicopathological features had higher circulating lncRNA DLEU1 level 
      than those with favorable clinical characteristics. Moreover, EC patients in the 
      high serum lncRNA DLEU1 group suffered worse overall survival and disease-free 
      survival than those in the low serum lncRNA DLEU1 group. Furthermore, 
      multivariate cox regression analysis displayed that the serum lncRNA DLEU1 served 
      as an independent prognostic factor for EC. CONCLUSIONS: Collectively, our study 
      suggests that serum lncRNA DLEU1 is a novel and promising biomarker for 
      prognostic estimation of EC.
FAU - Shan, Lixia
AU  - Shan L
AUID- ORCID: 0000-0002-9009-5175
AD  - Department of Gynecology, Shijiazhuang People's Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
FAU - Zhao, Tao
AU  - Zhao T
AD  - Department of Gynecology, Shijiazhuang People's Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Department of Gynecology, Shijiazhuang People's Hospital, Shijiazhuang, Hebei, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 0 (DLEU1 lncRNA, human)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Carcinogenesis/*genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Endometrial Neoplasms/*blood/genetics/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Humans
MH  - Middle Aged
MH  - Precancerous Conditions/*blood/genetics/pathology
MH  - Prognosis
MH  - RNA, Long Noncoding/*blood/genetics
PMC - PMC7750898
OTO - NOTNLM
OT  - endometrial cancer
OT  - long non-coding RNAs
OT  - prognosis prediction
OT  - serum DLEU1
OT  - survival
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/12/18 06:00
MHDA- 2021/11/09 06:00
PMCR- 2020/12/17
CRDT- 2020/12/17 05:29
PHST- 2020/12/17 05:29 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2020/12/17 00:00 [pmc-release]
AID - 10.1177_1533033820965589 [pii]
AID - 10.1177/1533033820965589 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820965589. doi: 
      10.1177/1533033820965589.